All In Biotech

Drug Trial Radar · NCT02826603

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,114

Actual

Start

Jun 22, 2016

Primary completion

Jul 9, 2018

Study completion Jul 9, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • SecukinumabDrug

    300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48

  • UstekinumabDrug

    Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12Time frame: Week 12
  2. Participants With IGA Mod 2011 0 or 1 at Week 12Time frame: Week 12

Locations

154 sites in 11 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Anniston, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Glendale, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Scottsdale, Arizona

  • Novartis Investigative Site

    Scottsdale, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Fort Smith, Arkansas

  • Novartis Investigative Site

    Hot Springs, Arkansas

  • Novartis Investigative Site

    Rogers, Arkansas

  • Novartis Investigative Site

    Bakersfield, California

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    California City, California

  • Novartis Investigative Site

    Encinitas, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Irvine, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Monica, California

  • Novartis Investigative Site

    Santa Rosa, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Trumbull, Connecticut

  • Novartis Investigative Site

    Aventura, Florida

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Cape Coral, Florida

  • Novartis Investigative Site

    Coral Gables, Florida

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Orange Park, Florida

  • Novartis Investigative Site

    South Miami, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Tampa, Florida

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.